These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 24259407)

  • 1. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
    Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
    Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
    Mookerjee RP; Mehta G; Balasubramaniyan V; Mohamed Fel Z; Davies N; Sharma V; Iwakiri Y; Jalan R
    J Hepatol; 2015 Feb; 62(2):325-31. PubMed ID: 25152204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
    Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
    Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
    Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
    Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
    Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
    Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
    Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
    United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis.
    Laleman W; Omasta A; Van de Casteele M; Zeegers M; Vander Elst I; Van Landeghem L; Severi T; van Pelt J; Roskams T; Fevery J; Nevens F
    Hepatology; 2005 Dec; 42(6):1382-90. PubMed ID: 16317694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
    Verbeke L; Farre R; Verbinnen B; Covens K; Vanuytsel T; Verhaegen J; Komuta M; Roskams T; Chatterjee S; Annaert P; Vander Elst I; Windmolders P; Trebicka J; Nevens F; Laleman W
    Am J Pathol; 2015 Feb; 185(2):409-19. PubMed ID: 25592258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
    Lee PC; Yang YY; Lee WP; Lee KC; Hsieh YC; Lee TY; Lin HC
    J Gastroenterol Hepatol; 2015 Mar; 30(3):628-37. PubMed ID: 25187428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy.
    Magdy YM; El-Kharashi OA; El-Waseef DAA; Nabih ES; Abd El Samad AA
    Exp Mol Pathol; 2018 Dec; 105(3):293-310. PubMed ID: 30308196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
    Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
    J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway.
    Tsai YL; Liu CW; Hsu CF; Huang CC; Lin MW; Huang SF; Li TH; Lee KC; Hsieh YC; Yang YY; Lee TY; Liu HM; Huang YH; Hou MC; Lin HC
    Clin Sci (Lond); 2020 Aug; 134(15):2055-2073. PubMed ID: 32725149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
    Fiorucci S; Distrutti E
    Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.